National Railway Company of Belgium

Bowman Issues Clarification Regarding Assignment with Canadian National Railway Company

Retrieved on: 
Friday, September 29, 2023

Bowman Consulting Group Ltd. (the “Company” or “Bowman”) (NASDAQ: BWMN), a national engineering services firm delivering infrastructure solutions to customers who own, develop, and maintain the built environment, is correcting a previously issued announcement to clarify that Canadian National Railway Company (“CN”) has only selected the Company for a stand-alone construction management services project in the Chicago area.

Key Points: 
  • Bowman Consulting Group Ltd. (the “Company” or “Bowman”) (NASDAQ: BWMN), a national engineering services firm delivering infrastructure solutions to customers who own, develop, and maintain the built environment, is correcting a previously issued announcement to clarify that Canadian National Railway Company (“CN”) has only selected the Company for a stand-alone construction management services project in the Chicago area.
  • The prior release erroneously characterized the award as a multi-year agreement for on-call engineering services at various CN locations throughout the United States.

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Friday, May 12, 2023

MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.
  • Baudax Bio expects to complete nonclinical studies and manufacturing data required to support the IND for BX3000 in late summer of 2023.
  • Financial Results for the Three Months Ended March 31, 2023
    As of March 31, 2023, Baudax Bio had cash and cash equivalents of $3.8 million.
  • Baudax Bio reported net loss from continuing operations of $(7.4) million, or $(3.19) per share, for the three months ended March 31, 2023.

Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000

Retrieved on: 
Tuesday, April 25, 2023

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. Results of the study showed that BX1000 met the primary endpoint of readiness for intubation (evaluated as “Good” or “Excellent”) at all dose levels assessed. No severe adverse events were observed in any dose regimen.

Key Points: 
  • MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
  • Results of the study showed that BX1000 met the primary endpoint of readiness for intubation (evaluated as “Good” or “Excellent”) at all dose levels assessed.
  • The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned clinical trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • Additionally, the clinical trial evaluated the safety and tolerability profile of BX1000 and rocuronium in this patient population.

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

Retrieved on: 
Thursday, December 8, 2022

This randomized, double-blind clinical trial will study BX1000 in approximately 80 adult patients, 18-65 years of age, who undergo elective surgery utilizing total intravenous anesthesia (TIVA) in an outpatient setting.

Key Points: 
  • This randomized, double-blind clinical trial will study BX1000 in approximately 80 adult patients, 18-65 years of age, who undergo elective surgery utilizing total intravenous anesthesia (TIVA) in an outpatient setting.
  • Patients will undergo elective surgery with an intravenous (IV) line for anesthesia and study drug administration.
  • “The initiation of this Phase II clinical study in patients undergoing elective surgery is an important step for the overall NMB program, and we look forward to data on BX1000’s safety, tolerability, and neuromuscular blocking profile,” said Gerri Henwood, Baudax Bio’s President and Chief Executive Officer.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Baudax Bio Announces Closing of $5 Million Public Offering

Retrieved on: 
Tuesday, December 6, 2022

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $5 million.

Key Points: 
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $5 million.
  • The Company intends to use the net proceeds from this offering for working capital, pipeline development activities and general corporate purposes.
  • The offering was made only by means of a prospectus which forms a part of the effective registration statement.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Baudax Bio Announces Pricing of $5 Million Public Offering

Retrieved on: 
Friday, December 2, 2022

The closing of the offering is expected to occur on or aboutDecember 6, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or aboutDecember 6, 2022, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to beapproximately $5 million.
  • The Company intends to use the net proceeds from this offering for working capital, pipeline development activities and general corporate purposes.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Baudax Bio Announces 1-for-40 Reverse Stock Split

Retrieved on: 
Wednesday, November 30, 2022

MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Companys Board of Directors has approved a 1-for-40 reverse stock split of its common shares (the Reverse Stock Split).

Key Points: 
  • MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Companys Board of Directors has approved a 1-for-40 reverse stock split of its common shares (the Reverse Stock Split).
  • At the effective time of the Reverse Stock Split, every forty (40) shares of Baudax Bios issued and outstanding common stock will be automatically converted into one (1) issued and outstanding share of common stock without any change in the par value of $0.01 per share.
  • No fractional shares of common stock will be issued as a result of the Reverse Stock Split.
  • The Reverse Stock Split impacts all holders of Baudax Bios common stock proportionally and will not impact any shareholders percentage ownership of common stock (except to the extent the reverse stock split results in any shareholder owning only a fractional share).

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 8, 2022

MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the three and nine months ended September 30, 2022, updated the status of the neuromuscular blocking (NMB) agent development program, provided key metrics around the ongoing commercialization of ANJESO (meloxicam) injection, and provided an overview of other corporate and financial developments.

Key Points: 
  • Baudax Bio expects to complete nonclinical studies and manufacturing data required to support the IND for BX3000 in the first half of 2023.
  • In August 2022, Baudax Bio announced that the United States Patent and Trademark Office (USPTO) had provided a Notice of Allowance for patent application No.
  • As of September 30, 2022, Baudax Bio had cash and cash equivalents of $5.6 million.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

Retrieved on: 
Monday, September 19, 2022

The shares of SeriesB Preferred Stock will be distributed to such recipients at 5:00p.m.

Key Points: 
  • The shares of SeriesB Preferred Stock will be distributed to such recipients at 5:00p.m.
  • Subject to certain limitations, each outstanding share of SeriesB Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of SeriesB Preferred Stock).
  • The SeriesB Preferred Stock will be uncertificated, and no shares of SeriesB Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Companys common stock held by such holder.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

Retrieved on: 
Thursday, September 8, 2022

A webcast of the presentation will be available on the Events page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors .

Key Points: 
  • A webcast of the presentation will be available on the Events page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors .
  • Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings.
  • Baudax Bio markets ANJESO, the first and only 24-hour, non-opioid, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain.
  • In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two clinical-stage, novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs.